SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项II期、开放标签研究，旨在研究聚乙二醇干扰素α 2a（PEG-IFN）长期维持治疗是否能降低HCV/HIV合并感染受试者的肝纤维化进展率。 将入组未接受过HCV治疗和既往接受过治疗的受试者。 预计全国范围内最多有180例受试者参与研究，其中10例受试者将在该研究中心招募。 研究持续时间为72 - 96周，根据受试者参与的研究组，将需要约18次访视。 研究程序将包括体格检查、血液和尿液检查、几项结局评估和EKG（如有指征）、眼科检查（如有指征）和肝活检。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, open-label study designed to study whether long-term maintenance with pegylated-interferon alfa 2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection. Both HCV treatment na¿ and previously treated subjects will be enrolled. Up to 180 subjects nationwide are expected to participate with ten subjects targeted for recruitment at this site. The study duration will be between 72 and 96 weeks and will require about 18 visits depending on which arm of the study subjects participate. Study procedures will include physical exams, blood and urine tests, several outcomes assessments, and EKG (if indicated), an eye exam (if indicated), and liver biopsies.